Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Caribou Biosciences (CRBU) Operating Expenses (2020 - 2025)

Historic Operating Expenses for Caribou Biosciences (CRBU) over the last 6 years, with Q3 2025 value amounting to $31.6 million.

  • Caribou Biosciences' Operating Expenses fell 2151.91% to $31.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $168.1 million, marking a year-over-year decrease of 486.65%. This contributed to the annual value of $176.6 million for FY2024, which is 1732.08% up from last year.
  • Caribou Biosciences' Operating Expenses amounted to $31.6 million in Q3 2025, which was down 2151.91% from $50.2 million recorded in Q2 2025.
  • In the past 5 years, Caribou Biosciences' Operating Expenses registered a high of $50.2 million during Q2 2025, and its lowest value of $14.8 million during Q1 2021.
  • Over the past 5 years, Caribou Biosciences' median Operating Expenses value was $34.6 million (recorded in 2023), while the average stood at $34.3 million.
  • In the last 5 years, Caribou Biosciences' Operating Expenses surged by 13966.27% in 2021 and then crashed by 2151.91% in 2025.
  • Quarter analysis of 5 years shows Caribou Biosciences' Operating Expenses stood at $23.0 million in 2021, then soared by 49.23% to $34.3 million in 2022, then increased by 19.64% to $41.0 million in 2023, then dropped by 0.12% to $41.0 million in 2024, then dropped by 22.84% to $31.6 million in 2025.
  • Its Operating Expenses stands at $31.6 million for Q3 2025, versus $50.2 million for Q2 2025 and $45.3 million for Q1 2025.